Skip to main content
Erschienen in: Drugs & Aging 12/2014

01.12.2014 | Systematic Review

Pharmacotherapy for Hypertension in Older Adults: A Systematic Review

Erschienen in: Drugs & Aging | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Hypertension increases with increasing age. Optimal treatment of hypertension is important to reduce cardiovascular disease. Recent guidelines for hypertension have made recommendations for older adults but are supported by evidence that includes younger individuals. This systematic review evaluates the benefits and harms of antihypertensive agents in adults aged ≥65 years.

Methods

We searched MEDLINE and ClinicalTrials.gov for studies from 1996 to 2014. Eligible studies included participants aged ≥65 years with hypertension. Eligible studies had clearly defined treatment assignments, blood pressure (BP) targets, and evaluated endpoints of cardiovascular morbidity, mortality, and/or harms of antihypertensive medications. We abstracted study characteristics, cardiovascular benefits, and harms.

Results

Thirty-one articles met the inclusion criteria. Most studies compared different antihypertensive agents and/or placebo groups. These studies consistently demonstrated reduced cardiovascular morbidity and mortality compared with no treatment. Seven studies examined optimal BP targets. Strict control [systolic BP (SBP) <140 mmHg] was not consistently better than mild control (SBP <150 mmHg) for adults aged ≥65 years. Mild SBP control benefitted subjects in all age ranges over 65 years. Few studies assessed and explicitly reported harms.

Conclusions

In this review, older adults with hypertension had decreased cardiovascular morbidity and mortality with antihypertensives compared with no treatment. Strict control was not consistently better than mild control in older adults. There was enormous heterogeneity in these studies, and reporting of harms stratified by age is lacking. The current evidence is insufficient to determine the safest, most beneficial hypertension regimen in older adults.
Literatur
1.
Zurück zum Zitat British Columbia Ministry of Health Services. Hypertension incidence and prevalence, age-specific rates, by gender 2001/2002. British Columbia: Ministry of Health Services; 2003. British Columbia Ministry of Health Services. Hypertension incidence and prevalence, age-specific rates, by gender 2001/2002. British Columbia: Ministry of Health Services; 2003.
3.
Zurück zum Zitat PRIMIS+. Hypertension statistics. 2008. PRIMIS+. Hypertension statistics. 2008.
4.
Zurück zum Zitat James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20. doi:10.1001/jama.2013.284427.PubMedCrossRef James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20. doi:10.​1001/​jama.​2013.​284427.PubMedCrossRef
5.
Zurück zum Zitat Sera LC, McPherson ML. Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy. Clin Geriatr Med. 2012;28:273–86.PubMedCrossRef Sera LC, McPherson ML. Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy. Clin Geriatr Med. 2012;28:273–86.PubMedCrossRef
6.
Zurück zum Zitat Belmin J, Abderrhamane M, Medjahed S, et al. Variability of blood pressure response to orthostatism and reproducibility of the diagnosis of orthostatic hypotension in elderly subjects. J Gerontol A Biol Sci Med Sci. 2000;55:M667–71.PubMedCrossRef Belmin J, Abderrhamane M, Medjahed S, et al. Variability of blood pressure response to orthostatism and reproducibility of the diagnosis of orthostatic hypotension in elderly subjects. J Gerontol A Biol Sci Med Sci. 2000;55:M667–71.PubMedCrossRef
7.
Zurück zum Zitat Kawaguchi T, Uyama O, Konishi M, Nishiyama T, Iida T. Orthostatic hypotension in elderly persons during passive standing: a comparison with young persons. J Gerontol A Biol Sci Med Sci. 2001;56(5):M273–80. Kawaguchi T, Uyama O, Konishi M, Nishiyama T, Iida T. Orthostatic hypotension in elderly persons during passive standing: a comparison with young persons. J Gerontol A Biol Sci Med Sci. 2001;56(5):M273–80.
8.
Zurück zum Zitat Lewis A, Lipsitz LA. Dynamics of stability: the physiologic basis of functional health and frailty. J Gerontol A Biol Sci Med Sci. 2002;57:B115–25.CrossRef Lewis A, Lipsitz LA. Dynamics of stability: the physiologic basis of functional health and frailty. J Gerontol A Biol Sci Med Sci. 2002;57:B115–25.CrossRef
9.
Zurück zum Zitat Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5:263–303.PubMedCrossRef Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5:263–303.PubMedCrossRef
10.
Zurück zum Zitat Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046–58.PubMedCentralPubMedCrossRef Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046–58.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Qureshi AI, Suri MF, Mohammad Y, Guterman LR, Hopkins LN. Isolated and borderline isolated systolic hypertension relative to long-term risk and type of stroke: a 20-year follow-up of the national health and nutrition survey. Stroke. 2002;33:2781–8.PubMedCrossRef Qureshi AI, Suri MF, Mohammad Y, Guterman LR, Hopkins LN. Isolated and borderline isolated systolic hypertension relative to long-term risk and type of stroke: a 20-year follow-up of the national health and nutrition survey. Stroke. 2002;33:2781–8.PubMedCrossRef
12.
Zurück zum Zitat Franklin SS, Jacobs MJ, Wong ND, L’Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37:869–74.PubMedCrossRef Franklin SS, Jacobs MJ, Wong ND, L’Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37:869–74.PubMedCrossRef
13.
Zurück zum Zitat Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010;100:S105–12.PubMedCentralPubMedCrossRef Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010;100:S105–12.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Uijen AA, Bakx JC, Mokkink HGA, van Weel C. Hypertension patients participating in trials differ in many aspects from patients treated in general practices. J Clin Epidemiol. 2007;60:330–5.PubMedCrossRef Uijen AA, Bakx JC, Mokkink HGA, van Weel C. Hypertension patients participating in trials differ in many aspects from patients treated in general practices. J Clin Epidemiol. 2007;60:330–5.PubMedCrossRef
15.
Zurück zum Zitat Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.PubMedCrossRef Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.PubMedCrossRef
16.
Zurück zum Zitat Ogihara T, Matsuzaki M, Umemoto S, et al. Combination therapy for hypertension in the elderly: a sub-analysis of the combination therapy of hypertension to prevent cardiovascular events (COPE) trial. Hypertens Res. 2012;35:441–8.PubMedCrossRef Ogihara T, Matsuzaki M, Umemoto S, et al. Combination therapy for hypertension in the elderly: a sub-analysis of the combination therapy of hypertension to prevent cardiovascular events (COPE) trial. Hypertens Res. 2012;35:441–8.PubMedCrossRef
17.
Zurück zum Zitat Saito I, Suzuki H, Kageyama S, Saruta T. Effect of antihypertensive treatment on cardiovascular events in elderly hypertensive patients: Japan’s Benidipine Research on Antihypertensive Effects in the Elderly (J-BRAVE). Clin Exp Hypertens. 2011;33:133–40.PubMedCrossRef Saito I, Suzuki H, Kageyama S, Saruta T. Effect of antihypertensive treatment on cardiovascular events in elderly hypertensive patients: Japan’s Benidipine Research on Antihypertensive Effects in the Elderly (J-BRAVE). Clin Exp Hypertens. 2011;33:133–40.PubMedCrossRef
19.
Zurück zum Zitat National Clinical Guideline Centre (UK). Hypertension: the clinical management of primary hypertension in adults: update of clinical guidelines 18 and 34. London: Royal College of Physicians (UK); 2011. (NICE Clinical Guidelines, no. 127.). http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0047679/. Accessed 26 Sep 2014. National Clinical Guideline Centre (UK). Hypertension: the clinical management of primary hypertension in adults: update of clinical guidelines 18 and 34. London: Royal College of Physicians (UK); 2011. (NICE Clinical Guidelines, no. 127.). http://​www.​ncbi.​nlm.​nih.​gov/​pubmedhealth/​PMH0047679/​.​ Accessed 26 Sep 2014.
20.
Zurück zum Zitat Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123:2434–506.PubMedCrossRef Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123:2434–506.PubMedCrossRef
21.
Zurück zum Zitat Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;31(7):1281–357. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;31(7):1281–357.
22.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9, W64. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9, W64.
23.
Zurück zum Zitat Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev. 2009;(4):CD000028. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev. 2009;(4):CD000028.
24.
Zurück zum Zitat Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121–3. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121–3.
25.
Zurück zum Zitat Ogihara T, Nakao K, Fukui T, et al. The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens Res. 2008;31:1595–601.PubMedCrossRef Ogihara T, Nakao K, Fukui T, et al. The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens Res. 2008;31:1595–601.PubMedCrossRef
26.
Zurück zum Zitat Peart S, Brennan PJ, Broughton P, et al. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J. 1992;304:405–12.CrossRef Peart S, Brennan PJ, Broughton P, et al. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J. 1992;304:405–12.CrossRef
27.
Zurück zum Zitat Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–86.PubMedCrossRef Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–86.PubMedCrossRef
28.
Zurück zum Zitat JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31:2115–27. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31:2115–27.
29.
Zurück zum Zitat Ogihara T, Saruta T, Rakugi H, et al.; Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56:196–202. Ogihara T, Saruta T, Rakugi H, et al.; Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56:196–202.
30.
Zurück zum Zitat Mori Y, Nishikawa Y, Iizuka T, et al. Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey. Drugs R D. 2011;11:171–90.PubMedCentralPubMedCrossRef Mori Y, Nishikawa Y, Iizuka T, et al. Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey. Drugs R D. 2011;11:171–90.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Saito I, Suzuki H, Kageyama S, Saruta T. Treatment of hypertension in patients 85 years of age or older: a J-BRAVE substudy. Clin Exp Hypertens. 2011;33:275–80.PubMedCrossRef Saito I, Suzuki H, Kageyama S, Saruta T. Treatment of hypertension in patients 85 years of age or older: a J-BRAVE substudy. Clin Exp Hypertens. 2011;33:275–80.PubMedCrossRef
32.
Zurück zum Zitat Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients. Am J Med. 2012;125:981–90.PubMedCrossRef Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients. Am J Med. 2012;125:981–90.PubMedCrossRef
33.
Zurück zum Zitat Yamazaki T, Kohro T, Chujo M, Ishigaki M, Hashimoto T. The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID). Hypertens Res. 2013;36:140–50.PubMedCrossRef Yamazaki T, Kohro T, Chujo M, Ishigaki M, Hashimoto T. The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID). Hypertens Res. 2013;36:140–50.PubMedCrossRef
34.
Zurück zum Zitat Lindholm LH, Anderson H, Ekbom T, et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet. 2001;358:539–44.PubMedCrossRef Lindholm LH, Anderson H, Ekbom T, et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet. 2001;358:539–44.PubMedCrossRef
35.
Zurück zum Zitat Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet. 1999;354:1751–6.PubMedCrossRef Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet. 1999;354:1751–6.PubMedCrossRef
36.
Zurück zum Zitat Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281–5.PubMedCrossRef Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281–5.PubMedCrossRef
37.
Zurück zum Zitat Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the study on cognition and prognosis in the elderly (SCOPE). J Am Coll Cardiol. 2004;44:1175–80.PubMed Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the study on cognition and prognosis in the elderly (SCOPE). J Am Coll Cardiol. 2004;44:1175–80.PubMed
38.
Zurück zum Zitat Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish trial in old patients with hypertension-2. J Hypertens. 2000;18:1671–5.PubMedCrossRef Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish trial in old patients with hypertension-2. J Hypertens. 2000;18:1671–5.PubMedCrossRef
39.
Zurück zum Zitat Ekbom T, Dahlof B, Hansson L, Lindholm LH, Schersten B, Wester PO. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-hypertension study. J Hypertens. 1992;10:1525–30.PubMedCrossRef Ekbom T, Dahlof B, Hansson L, Lindholm LH, Schersten B, Wester PO. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-hypertension study. J Hypertens. 1992;10:1525–30.PubMedCrossRef
40.
Zurück zum Zitat Ekbom T, Linjer E, Hedner T, et al. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-hypertension-2. Blood Press. 2004;13:137–43.PubMedCrossRef Ekbom T, Linjer E, Hedner T, et al. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-hypertension-2. Blood Press. 2004;13:137–43.PubMedCrossRef
41.
Zurück zum Zitat Gueyffier F, Bulpitt C, Boissel JP. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet. 1999;353:793–6.PubMedCrossRef Gueyffier F, Bulpitt C, Boissel JP. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet. 1999;353:793–6.PubMedCrossRef
42.
Zurück zum Zitat Furberg CD, Wright JT Jr, Davis BR, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Am Med Assoc. 2002;288:2981–97.CrossRef Furberg CD, Wright JT Jr, Davis BR, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Am Med Assoc. 2002;288:2981–97.CrossRef
43.
Zurück zum Zitat Cushman WC, Davis BR, Pressel SL, et al. Mortality and morbidity during and after the antihypertensive and lipid-lowering treatment to prevent heart attack trial. J Clin Hypertens. 2012;14:20–31.CrossRef Cushman WC, Davis BR, Pressel SL, et al. Mortality and morbidity during and after the antihypertensive and lipid-lowering treatment to prevent heart attack trial. J Clin Hypertens. 2012;14:20–31.CrossRef
44.
Zurück zum Zitat Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–92.PubMedCrossRef Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–92.PubMedCrossRef
45.
Zurück zum Zitat Solfrizzi V, Scafato E, Frisardi V, et al. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age. 2013;35:441–53.PubMedCentralPubMedCrossRef Solfrizzi V, Scafato E, Frisardi V, et al. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age. 2013;35:441–53.PubMedCentralPubMedCrossRef
46.
Zurück zum Zitat Hansson L, Zanchetti A. The hypertension optimal treatment (HOT) study: 12-month data on blood pressure and tolerability. With special reference to age and gender. Blood Press. 1995;4:313–9.PubMedCrossRef Hansson L, Zanchetti A. The hypertension optimal treatment (HOT) study: 12-month data on blood pressure and tolerability. With special reference to age and gender. Blood Press. 1995;4:313–9.PubMedCrossRef
47.
Zurück zum Zitat Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7:683–9.PubMedCrossRef Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7:683–9.PubMedCrossRef
48.
Zurück zum Zitat Peters R, Beckett N, Burch L, et al. The effect of treatment based on a diuretic (indapamide) ± ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). Age Ageing. 2010;39:609–16.PubMedCrossRef Peters R, Beckett N, Burch L, et al. The effect of treatment based on a diuretic (indapamide) ± ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). Age Ageing. 2010;39:609–16.PubMedCrossRef
49.
Zurück zum Zitat Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to hypertension in the very elderly randomised controlled trial. BMJ. 2011;344:d7541.PubMedCrossRef Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to hypertension in the very elderly randomised controlled trial. BMJ. 2011;344:d7541.PubMedCrossRef
50.
Zurück zum Zitat Bulpitt CJ, Beckett NS, Cooke J, et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens. 2003;21:2409–17.PubMedCrossRef Bulpitt CJ, Beckett NS, Cooke J, et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens. 2003;21:2409–17.PubMedCrossRef
51.
Zurück zum Zitat Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.PubMedCrossRef Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.PubMedCrossRef
52.
Zurück zum Zitat Wake Forest University Baptist Medical Center. Systolic blood pressure intervention trial: memory and cognition in decreased hypertension [ClinicalTrials.gov identifier NCT01206062]. US National Institutes of Health, ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT01206062. Accessed 20 Sep 2013. Wake Forest University Baptist Medical Center. Systolic blood pressure intervention trial: memory and cognition in decreased hypertension [ClinicalTrials.gov identifier NCT01206062]. US National Institutes of Health, ClinicalTrials.gov. http://​clinicaltrials.​gov/​show/​NCT01206062. Accessed 20 Sep 2013.
Metadaten
Titel
Pharmacotherapy for Hypertension in Older Adults: A Systematic Review
Publikationsdatum
01.12.2014
Erschienen in
Drugs & Aging / Ausgabe 12/2014
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-014-0219-8

Weitere Artikel der Ausgabe 12/2014

Drugs & Aging 12/2014 Zur Ausgabe

Acknowledgement to Referees

Acknowledgement to Referees

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.